Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

SEC Filings

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
Filing date Form Description View
Mar 31, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000033.pdf
0001808805-22-000033.rtf
0001808805-22-000033.xls
View HTML
Mar 4, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000026.pdf
0001808805-22-000026.rtf
0001808805-22-000026.xls
View HTML
Mar 2, 2022 424B3

Form of prospectus reflecting facts events constituting substantive change from last form

0001628280-22-004652.pdf
0001628280-22-004652.rtf
0001628280-22-004652.xls
View HTML
Mar 1, 2022 EFFECT

EFFECT

9999999995-22-000531.pdf
9999999995-22-000531.rtf
9999999995-22-000531.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000020.pdf
0001808805-22-000020.rtf
0001808805-22-000020.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000022.pdf
0001808805-22-000022.rtf
0001808805-22-000022.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000021.pdf
0001808805-22-000021.rtf
0001808805-22-000021.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000024.pdf
0001808805-22-000024.rtf
0001808805-22-000024.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000019.pdf
0001808805-22-000019.rtf
0001808805-22-000019.xls
View HTML
Feb 25, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000023.pdf
0001808805-22-000023.rtf
0001808805-22-000023.xls
View HTML

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page Next ›
  • Last page Last »
Displaying 71 - 80 of 191 results

Data provided by Kaleidoscope.

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms